HC Wainwright & Co. Reiterates Buy on First Wave BioPharma, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on First Wave BioPharma (NASDAQ:FWBI) and maintained a $10 price target.
June 13, 2023 | 3:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First Wave BioPharma (NASDAQ:FWBI) receives a reiterated Buy rating and a maintained $10 price target from HC Wainwright & Co. analyst Yi Chen.
The reiterated Buy rating and maintained $10 price target by HC Wainwright & Co. analyst Yi Chen indicates a positive outlook for First Wave BioPharma. This news is directly related to the company and is likely to have a positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100